Annual Report 2020

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2020 151 The United Laboratories International Holdings Limited Annual Report 2020 Name of subsidiaries Place of incorporation/ establishment Issued and fully paid share capital/ registered capital Attributable equity interest held by the Company Principal activities and place of operation (Note a) 2020 2019 成都樂邦生物醫藥科技有限公司 (Note c) The PRC RMB1,000,000 100% 100% Investment holding in the PRC 成都智匯城有限公司 (Note c) The PRC RMB10,000,000 100% 100% Investment holding in the PRC 聯邦制藥（中山）有限公司 (Note c) The PRC RMB50,000,000 100% 100% Manufacturing and sale of pharmaceutical products and food production in the PRC Notes: (a) Other than The United Laboratories (Hong Kong) Holding Limited, all subsidiaries are indirectly held by the Company. (b) A wholly foreign-owned enterprise established in the PRC. (c) A company established in the PRC with limited liability. (d) A joint stock limited liability company established in the PRC. (e) A company established in the PRC during the year ended 31 December 2020. (f) 珠海聯邦制藥股份有限公司 issued unsecured corporate bonds which are listed on the Shanghai Stock Exchange at 31 December 2019. Details are set out in Note 29. At 31 December 2020, none of the subsidiaries had issued any debt securities. At 31 December 2019, none of the subsidiaries had issued any debt securities except for 珠海聯邦制藥股份有限公司 which has issued RMB1,100,000,000 of bonds, in which the Group has no financial interest. 45. LIST OF SUBSIDIARIES (Continued)